$95.64—Stale · unknown old
NYSE • Last print unknown ago
$95.64—Stale · unknown old
Invesco Biotechnology & Genome ETF (PBE) focuses on investing in biotechnology and genomics companies, primarily in the United States. The ETF's competitive position is bolstered by its diversified exposure to high-growth sectors within healthcare, targeting companies involved in drug development, genetic research, and innovative therapies.
PBE generates revenue primarily through management fees based on the total assets under management. The ETF's focus on biotechnology and genomics allows it to capitalize on high-growth trends in healthcare, providing a unique value proposition to investors seeking exposure to this volatile but potentially lucrative sector.
Performance of underlying biotech stocks, particularly those in drug development and genomic research
Regulatory approvals for key drugs from companies within the ETF
Market sentiment towards healthcare innovation and biotech investments
Changes in investor appetite for risk, particularly in growth sectors
Technological disruption in biotech, leading to rapid obsolescence of certain therapies
Regulatory changes affecting drug approval processes and pricing
Increased competition from other ETFs focusing on biotech or healthcare sectors
Market volatility affecting investor sentiment towards high-growth sectors
Liquidity risk associated with the underlying assets in the ETF
Potential for high expense ratios if AUM declines significantly
moderate - The ETF is sensitive to economic cycles as healthcare spending can fluctuate with consumer confidence and economic conditions.
Rising interest rates may lead to higher borrowing costs for biotech firms, potentially dampening innovation and investment in the sector, which could negatively impact the ETF's performance.
minimal - The ETF does not have direct credit exposure but may be affected by the credit conditions of the underlying companies.
growth - Investors seeking high growth potential in the biotechnology and genomics sectors are likely to be attracted to this ETF.
high - The ETF is expected to have high volatility due to the nature of the biotech sector.